Lemaitre Vascular Q3 2026 earnings

LMAT · 2026-11-04 16:40 AMC ET · 8-K on SEC

Revenue growth slowed to 11% YoY, but gross margin expanded and operating income rose 13% YoY.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$67.97M+11.3%—Ex. 99.1, income statement
EPS (GAAP)$0.66-14.3%—Ex. 99.1, income statement
EPS (adjusted)$0.65+4.8%—Ex. 99.1, income statement
Net income$15.02M-13.5%—Ex. 99.1, income statement
Adj. EBITDA$20.50M+6.5%—Ex. 99.1, income statement
Adj. EBITDA margin30.2%+1.2 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Artegraft+18%——Sales increased 18% in the quarter
Grafts+20%——Drove Q3 growth
Shunts+14%——Drove Q3 growth
EMEA+18%——Sales increased 18%
Americas+9%——Sales increased 9%
APAC+5%——Sales increased 5%

Margins and costs

  • Gross margin 71.7% (prior 72.1%, change -0.4 pp)
  • Operating expenses $31.01M (+21.0% YoY)
  • One-offs in the quarter Employee retention tax credit impact of $0.13 per share; Acquisition of vascular assets from B. Braun for $19.2mm
  • Effective tax rate 23.6% (prior-year 23.1%, year-to-date 22.4%)
  • Non-GAAP bridge Adds back employee retention tax credit, interest expense, depreciation/amortization, and taxes to GAAP net income to arrive at Adjusted EBITDA.

KPIs

MetricActualPrior quarterPrior yearChange
Headcount6786609/30/2025+7%
Rep count171——+13%
Cash and cash equivalents$27.49M$26.63M—+3.2%

Guidance

MetricGuidePrior guideChange
Net sales per guidance (midpoint)$70.90M——
Adjusted projected net sales$71.41M——

What drove it

  • Revenue story Q3 organic growth of 12% comprised of 7% price and 5% units; Grafts (+20%) and shunts (+14%) drove growth; Artegraft sales increased 18% despite currency headwinds.
  • EPS story EPS declined YoY due to higher operating expenses and a lower tax rate, despite revenue growth.
  • One-off check Employee retention tax credit impact of $0.13 per share (vs. $0.13 in prior year) and acquisition of B. Braun assets for $19.2mm.

The good

  • Gross margin expanded 90 bps YoY to 71.7%
  • Operating income increased 13% YoY to $17.70M
  • Adjusted EBITDA margin increased 1.2 pp to 30.2%

The bad

  • Revenue growth slowed to 11% YoY
  • Operating expenses increased 18% YoY
  • EPS declined 14% YoY

The ugly

  • none

Open questions

  • What is the specific impact of the B. Braun acquisition on Q3 and full-year 2026 sales?
  • What caused the decline in EPS YoY despite revenue growth?
  • Why did operating expenses increase 18% YoY?
Full release

Lemaitre Vascular (LMAT) earnings release, November 4, 2026

Lemaitre Vascular Inc (LMAT) · Form 8-K, Item 2.02 · Filed · SEC filing

LeMaitre Q3 2026 Financial Results

BURLINGTON, MA, November 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q3 2026:

Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was comprised of 7% price and 5% units.

Gross margin of 71.7% was up 90 bps (vs. adjusted) due to higher ASPs and operational efficiencies. Operating expenses increased 18% (vs. adjusted) due to Q3 2025 belt-tightening. Headcount of 678 increased 7% versus 9/30/2025 while rep count increased 13% to 171.

In October, the company acquired certain vascular assets from B. Braun for $19.2mm. These polyester and silver-coated grafts, valve cutters and vein strippers recorded sales of $9.4mm in 2025, all outside of North America. Sales will transition into LeMaitre’s channel over the next

18-24 months as B. Braun’s customer contracts conclude or transfer to

LeMaitre. During this transition, LeMaitre will receive a portion of the profits on B. Braun-originated sales.

Chairman/CEO George LeMaitre said,

“We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding

31-country sales force.”

Business Outlook

Quarterly Dividend

On October 27, 2026, the

Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on December 3, 2026, to stockholders of record on November 19, 2026.

Share Repurchase Program

On February 19, 2026, the

Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company’s website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company’s website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than

200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of

Non-GAAP

Financial Measures

LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP.

Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations.

Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for Q3 2026 operating income, gross margin, operating expense and EPS, as well as operating income and EPS guidance, adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing growth in these measures excluding those effects provides an alternative and meaningful view of the

Company’s profitability.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to

Non-GAAP

Financial Measures” below.

Financial statements

Income Statement

For the three months ended — (unaudited) (in thousands)

For the three months ended – September 30, 2026For the three months ended – September 30, 2025For the nine months ended – September 30, 2026For the nine months ended – September 30, 2025
Net sales67,97061,046204,903185,149
Cost of sales19,26515,09157,03852,800
Gross profit48,70545,955147,865132,349
Operating expenses:
Sales and marketing14,50611,92343,42941,030
General and administrative12,08310,75035,23931,633
Research and development4,4212,97013,32810,606
Total operating expenses31,01025,64391,99683,269
Income from operations17,69520,31255,86949,080
Other income (expense):
Investment income3,3653,86410,0759,747
Interest expense-1,304-1,297-3,906-3,886
Other income (loss), net-82-306-503-57
Income before income taxes19,67422,57361,53554,884
Provision for income taxes4,6505,21113,78212,732
Net income15,02417,36247,75342,152
Earnings per share of common stock
Basic0.660.772.091.86
Diluted0.650.752.071.84
Weighted - average shares outstanding:
Basic22,87122,66022,84422,615
Diluted23,07124,39223,06422,915
Cash dividends declared per common share0.250.20.750.6

Income Statement

For the three months ended — (unaudited) (in thousands)

For the three months ended – September 30, 2026For the three months ended – September 30, 2025For the nine months ended – September 30, 2026For the nine months ended – September 30, 2025
Reconciliation between GAAP Net Income and Non-GAAP Adjusted EBITDA
Net income as reported15,02417,36247,75342,152
Employee retention tax credit, net-3,380-3,380
Interest (income) expense, net-2,061-2,567-6,169-5,861
Amortization and depreciation expense2,8852,6128,1707,812
Provision for income taxes4,6505,21113,78212,732
Adjusted EBITDA20,49819,23863,53653,455
Adjusted EBITDA percentage increase7.0%19.0%

Income Statement

(unaudited) (in thousands)

For the three months ended September 30, 2026
Net sales as reported67,970
Impact of currency exchange rate fluctuations439
Adjusted net sales68,409
For the three months ended September 30, 2025
Net sales as reported61,046
Adjusted net sales61,046
Adjusted net sales increase for the three months ended September 30, 20267,363
For the three months ended September 30, 2026
Gross margin as reported71.7
Adjusted gross margin71.7
For the three months ended September 30, 2025
Gross margin as reported75.3
Employee Retention Tax Credit impact-4.5
Adjusted gross margin70.8
For the three months ended September 30, 2026
Operating expense as reported31,010
Adjusted operating expense31,010
For the three months ended September 30, 2025
Operating expense as reported25,643
Employee Retention Tax Credit impact667
Adjusted operating expense26,310
Adjusted operating expense increase for the three months ended September 30, 20264,700
For the three months ended September 30, 2026
Operating income as reported17,695
Adjusted operating income17,695
For the three months ended September 30, 2025
Operating income as reported20,312
Employee Retention Tax Credit impact-3,380
Adjusted operating income16,932
Adjusted operating income increase for the three months ended September 30, 2026763
For the three months ended September 30, 2026
Earnings per share as reported0.65
Adjusted earnings per share0.65
For the three months ended September 30, 2025
Earnings per share as reported0.75
Employee Retention Tax Credit impact-0.13
Adjusted earnings per share0.62
Adjusted earnings per share increase for the three months ended September 30, 20260.03

Income Statement

(unaudited) (in thousands)

For the three months ending December 31, 2026
Net sales per guidance (midpoint)70,900
Impact of currency exchange rate fluctuations507
Adjusted projected net sales71,407

Balance Sheet

September 30, 2026 — (amounts in thousands)

September 30, 2026 – (unaudited)December 31, 2025
Current assets:
Cash and cash equivalents27,49328,244
Short-term marketable securities362,228330,876
Accounts receivable, net35,87633,610
Inventory and other deferred costs71,27270,422
Prepaid expenses and other current assets8,6425,080
Total current assets505,511468,232
Property and equipment, net30,46526,997
Right-of-use leased assets18,50315,762
Goodwill65,94565,945
Other intangibles, net29,29533,089
Deferred tax assets746759
Other assets5,5674,906
Total assets656,032615,690
Current liabilities:
Accounts payable4,1593,646
Accrued expenses26,68629,411
Acquisition-related obligations583322
Lease liabilities - short-term3,1922,944
Total current liabilities34,62036,323
Convertible senior notes, net169,317168,645
Lease liabilities - long-term16,34214,003
Deferred tax liabilities2,1671,735
Other long-term liabilities1,4551,468
Total liabilities223,901222,174
Stockholders’ equity
Common stock245244
Additional paid-in capital238,938228,407
Retained earnings215,324184,715
Accumulated other comprehensive loss-4,460-2,411
Treasury stock-17,916-17,439
Total stockholders’ equity432,131393,516
Total liabilities and stockholders’ equity656,032615,690

Cash Flow

For the nine months ended — (unaudited) (in thousands)

For the nine months ended – September 30, 2026For the nine months ended – September 30, 2025
Operating activities
Net income47,75342,152
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization8,1707,813
Stock-based compensation6,0565,730
Amortization of issuance costs on convertible notes672653
Non-cash investment income-253
Provision for inventory write-downs2,5481,893
Provision for credit losses675455
Foreign currency transaction effect on income316-79
Changes in operating assets and liabilities:
Accounts receivables-3,347-1,403
Inventory and other deferred costs-3,584-6,805
Prepaid expenses and other assets-4,2441,639
Accounts payable and other liabilities-6365,327
Accrued interest-1,078719
Net cash provided by operating activities53,04858,094
Investing activities
Purchases of short-term marketable securities-390,987-43,015
Purchases of property and equipment-7,429-5,006
Payments related to acquisitions, net of cash acquired-194-95

Forward-Looking Statements... (trunc’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other regulatory reviews, affecting our ability to market and sell our products domestically and internationally; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; competition from other medical device companies and alternative medical technologies; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form

10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Contact: ir@lemaitre.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lemaitre Vascular earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.